MEDVi vs OrderlyMeds (2026): prices, structure, verdict

On tirzepatide, OrderlyMeds↗ is cheaper: $299 versus $399 a month all-in — a $100 monthly gap, $1,200 across a year of maintenance dosing.

Updated 2026-08-10 · figures captured 2026-08-09 · how we verify

On semaglutide, OrderlyMeds is cheaper: $149 versus $299 a month all-in — a $150 monthly gap, $1,800 across a year of maintenance dosing.

§ Side by side

§ Each record, read aloud

The two records, condensed

MEDVi: the record, condensed

MEDVi’s tirzepatide program bills $399 a month once every mandatory fee is counted, measured at the 10 mg maintenance basis. Because pricing is flat across the ladder (2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available)), a dose increase at MEDVi is a clinical event and not a billing one. Whatever your prescriber decides, the invoice does not move, which makes this one of the few programs whose headline figure you can actually plan a year around.

There is no membership line. $399 is the billed total — consultation and clinical review are inside it, and no platform fee recurs beside it, which removes the most common way advertised GLP-1 prices understate billed ones.

Context for that figure: it ranks #14 of 17 in the verified tirzepatide index — $184/month above the floor (NexLife↗, $215) — and sits $50 under the brand benchmark (Zepbound (LillyDirect↗), $449 at maintenance). Annualized, a monthly-billed year here runs $4,788.

Start with the load-bearing figure: $299 a month, all-in, is what MEDVi charges for semaglutide at the 2.4 mg basis. Because pricing is flat across the ladder (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg), a dose increase at MEDVi is a clinical event and not a billing one. Whatever your prescriber decides, the invoice does not move, which makes this one of the few programs whose headline figure you can actually plan a year around.

Nothing recurs on top: no membership, no platform fee, no “provider access” line. The $299 is the whole subscription, which makes MEDVi unusually easy to compare and unusually easy to leave.

To place the number: #18 of 20 verified programs, with the floor $166/month below at Oak Longevity ($133); the approved-product yardstick (Wegovy (NovoCare↗)) sits at $349, so the compounded case here is worth $50 a month. A year at this figure: $3,588 monthly-billed.

Operationally at MEDVi: shipping included; commitment 12-month plan for the lowest rate; cancellation 12-month plan applies to lowest rate; pharmacy not publicly named — ask in writing before paying; states: priced differently in CA/NC on some plans; evidence source-verified, captured 2026-08-05. The full record with source and archive links: the MEDVi page · visit MEDVi ↗

OrderlyMeds: the record, condensed

OrderlyMeds’s tirzepatide program bills $299 a month once every mandatory fee is counted, measured at the 10 mg maintenance basis. Because pricing is flat across the ladder (2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available)), a dose increase at OrderlyMeds is a clinical event and not a billing one. Whatever your prescriber decides, the invoice does not move, which makes this one of the few programs whose headline figure you can actually plan a year around.

There is no membership line. $299 is the billed total — consultation and clinical review are inside it, and no platform fee recurs beside it, which removes the most common way advertised GLP-1 prices understate billed ones.

Context for that figure: it ranks #8 of 17 in the verified tirzepatide index — $84/month above the floor (NexLife, $215) — and sits $150 under the brand benchmark (Zepbound (LillyDirect), $449 at maintenance). Annualized, a monthly-billed year here runs $3,588.

Start with the load-bearing figure: $149 a month, all-in, is what OrderlyMeds charges for semaglutide at the 2.4 mg basis. It is a flat structure: 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg all bill identically. In a market where most low advertised prices quietly belong to the starter dose, a flat figure is the difference between a quote and a teaser.

Nothing recurs on top: no membership, no platform fee, no “provider access” line. The $149 is the whole subscription, which makes OrderlyMeds unusually easy to compare and unusually easy to leave.

To place the number: #4 of 20 verified programs, with the floor $16/month below at Oak Longevity ($133); the approved-product yardstick (Wegovy (NovoCare)) sits at $349, so the compounded case here is worth $200 a month. A year at this figure: $1,788 monthly-billed.

Operationally at OrderlyMeds: shipping included; commitment none stated; cancellation not published; pharmacy not publicly named — ask in writing before paying; states: not published; evidence no public price, captured 2026-08-05. The full record with source and archive links: the OrderlyMeds page · visit OrderlyMeds ↗

Tirzepatide: the duel in full

The tirzepatide arithmetic between these two is short: $299 (OrderlyMeds) against $399 (MEDVi). $100 a month sounds survivable; $1,200 a year is a decision.

Both figures are dose-flat, which is the cleanest possible comparison: two ceilings, no titration surprises on either side, and the $100 gap is exactly what it appears to be.

Semaglutide: the duel in full

Put the two semaglutide figures side by side and hold them there: OrderlyMeds at $149, MEDVi at $299 — a $150 monthly spread that compounds to $1,800 over a maintenance year and $3,600 over two.

Both figures are dose-flat, which is the cleanest possible comparison: two ceilings, no titration surprises on either side, and the $150 gap is exactly what it appears to be.

Translate the $100/month spread into medication: $1,200 a year equals roughly 4.0 months of therapy at the cheaper program’s rate. That is the honest unit for gaps in this market — months of treatment, not abstract dollars — and it is why small-looking monthly differences decide long courses.

On best published rate — the lower of each program’s month-to-month price and its labeled 12-month-plan rate, which is the sort most price roundups quietly run — the duel reads: MEDVi $399/mo month-to-month versus OrderlyMeds $299/mo month-to-month. Same winner on both bases — OrderlyMeds leads whether you compare month-to-month prices or committed-plan rates, which makes this one of the cleaner verdicts in the index. Prepaid rates are upfront commitments with refund terms to verify before they count.

§ The clock, run forward

Three, six, twelve, twenty-four months — best path each way

3 months: MEDVi $1,197 monthly; OrderlyMeds $897 monthly — best path favors OrderlyMeds by $300. 6 months: MEDVi $2,394 monthly; OrderlyMeds $1,794 monthly — best path favors OrderlyMeds by $600. 12 months: MEDVi $4,788 monthly; OrderlyMeds $3,588 monthly — best path favors OrderlyMeds by $1,200. 24 months: MEDVi $9,576 monthly; OrderlyMeds $7,176 monthly — best path favors OrderlyMeds by $2,400.

Prepaid paths above are billed upfront and assume the published rate holds (the 24-month figures extend the 12-month rate, an assumption worth naming). The honest reading: over short horizons the monthly gap decides; over long horizons the prepaid ladders and structural traps (dose tiers, memberships) take over — which is exactly the split the verdict section below scores.

The same clock, on semaglutide

3 mo: MEDVi $897 vs OrderlyMeds $447 — $450 to OrderlyMeds. 6 mo: MEDVi $1,794 vs OrderlyMeds $894 — $900 to OrderlyMeds. 12 mo: MEDVi $3,588 vs OrderlyMeds $1,788 — $1,800 to OrderlyMeds. 24 mo: MEDVi $7,176 vs OrderlyMeds $3,576 — $3,600 to OrderlyMeds.

Same rules as above: prepaid figures are upfront commitments, and the 24-month lines extend the 12-month rate as a stated assumption. Where the two molecules crown different winners between these two programs, that split is itself the finding — molecule choice and provider choice are separate decisions.

§ Structure vs structure

Everything besides the price

Coverage: MEDVi publishes “priced differently in CA/NC on some plans”; OrderlyMeds publishes “not published” — for anything short of an explicit 50-state claim, intake is the final word.

Neither names its pharmacy publicly — the single most useful disclosure in this category, missing on both sides; ask each, in writing, before paying either.

Exit terms: MEDVi — 12-month plan for the lowest rate; 12-month plan applies to lowest rate. OrderlyMeds — none stated; not published.

Evidence: MEDVi source-verified (captured 2026-08-05); OrderlyMeds no public price (2026-08-05). Where a figure is stated-not-verified, weight it accordingly — it is a claim we could not capture on the company’s own pages.

A rule that has held across this index: disclosure predicts disclosure. Whichever of these two publishes more — pharmacies, states, exit terms — is usually the one whose invoice matches its ad.

In the full tirzepatide index these two sit at #14 and #8 of 17: between them lie 5 other programs, and the whole ladder is at cheapest tirzepatide providers. In the full semaglutide index these two sit at #18 and #4 of 20: between them lie 13 other programs, and the whole ladder is at cheapest semaglutide providers.

§ If you move

Switching between MEDVi and OrderlyMeds

Prescriptions do not transfer like phone numbers: moving in either direction means completing the destination’s intake and having its prescriber write a new patient-specific prescription. The mechanics that prevent a bad month: confirm the destination serves your state and quotes your current dose in writing before cancelling anything; time the first new shipment to overlap the last old one rather than gap it; cancel the origin per its published terms (MEDVi: 12-month plan applies to lowest rate; OrderlyMeds: not published) and screenshot the confirmation; and never leave a prepaid balance stranded — which is the standing argument for prepaying only after a program has already earned a few monthly cycles.

§ Verdict by situation

Which one, for whom

§ More pairings